ReviewCurrent allergy and asthma reports2013
Which biomarkers are effective for identifying Th2-driven inflammation in asthma?
Review in Current allergy and asthma reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Integrated Bioinformatics and Experimental Validation of Inflammatory Cytokine-Related Hub Genes in Pediatric Asthma.Journal of asthma and allergy · 2026Article
- Frequent exacerbator-a novel endotype of pediatric asthma.The Journal of allergy and clinical immunology · 2025Review
- Identifying key genes and functionally enriched pathways in Th2-high asthma by weighted gene co-expression network analysis.BMC medical genomics · 2022Article
- Periostin - A Novel Systemic Biomarker for Eosinophilic Airway Inflammation: A Case Control Study.Journal of clinical and diagnostic research : JCDR · 2016Article
- Loki zupa (Luooukezupa) decoction reduced airway inflammation in an OVA-induced asthma mouse model.Chinese medicine · 2016Article
- Article
- Protective effects of the polyphenol sesamin on allergen-induced T(H)2 responses and airway inflammation in mice.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recognition of asthma as a heterogeneous disease revealed different potential molecular targets and urged the development of targeted, customized treatment modalities. Evidence was provided for different inflammatory subsets of asthma and more recently, further refined to T helper (Th)2-high and Th2-low subphenotypes with different responsiveness to standard and targeted pharmacotherapy. Given these differences in immunology and pathophysiology, proof of concept studies of novel treatment modalities for asthma should be performed in adequate, well-defined phenotypes. In this review, we describe both existing and novel biomarkers of Th2-inflammation in asthma that can be applied to classify asthma subphenotypes in clinical studies and for treatment monitoring.
Indexed as
Identifiers
23918590What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.